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Sill and co-workers1 report that germline variation in
semaphorin 4A (SEMA4A) inﬂuences colorectal cancer (CRC)
risk. This stems from identifying the SEMA4A p.Val78Met
variant in one kindred with familial colorectal cancer type X
(FCCTX) and subsequently p.Gly484Ala (c.1451G4C,
rs148744804) and p.Ser326Phe (c.977C4T) mutations along
with the single nucleotide polymorphism (SNP) p.Pro682Ser
(c.2044C4T, rs76381440) among an additional 53 FCCTX
cases. In comparing the frequency of rs76381440 genotype
in 47 FCCTX cases and 1,138 controls, c.2044T carrier
status was reported to be associated with 6.79-fold increased
CRC risk1.
Here, we report a well-powered study that casts doubt on
SEMA4A as a CRC predisposition gene. This has important
implications for clinical genetics because inappropriate screening
or intervention might be recommended to carriers.
First, we studied the contribution of the recurrent variants,
rs148744804 and rs76381440, to CRC analysing 6,856 CRC cases
and 10,090 controls from six European populations as previously
described2,3. These comprised (1) 3,666 English case patients
(n¼ 250 from the CORGI study; n¼ 957 from the QUASAR
study; n¼ 1,168 from NSCCG; n¼ 1,291 from a Leeds case–
control series) and 6,140 control patients (n¼ 5,694 from the
1958 Birth Cohort; n¼ 446 from the Leeds series); (2) 2,052
Scottish CRC cases and 2,004 Scottish controls (n¼ 1,452 from
the 1935 and 1928 Lothian birth cohorts; n¼ 552 from
generation Scotland); (3) 276 Spanish cases and 284 controls;
(4) 800 Dutch samples (n¼ 337 Leiden cases and n¼ 337
controls; n¼ 74 Groningen cases and n¼ 52 controls);
(5) 199 Portuguese cases and 186 controls and (6) 1,339
German samples (n¼ 77 Heidelberg cases and n¼ 88 controls;
n¼ 175 Kiel cases and n¼ 999 controls). Collectively these
samples provide499% power (a¼ 0.05) to detect the lower limit
of the point estimate reported by Sill and co-workers for the
association between p.Pro682Ser and CRC1) (odds ratio
[OR]¼ 2.6).
We used Inﬁnium HumanExome BeadChips (Illumina San
Diego, CA) to genotype our samples as previously described2,3
and extracted the genotypes for rs148744804 and rs76381440. We
validated genotyping by sequencing 541 random samples,
providing very strong concordance (r2¼ 1.0 and 0.99 for
rs148744804 and rs76381440, respectively; Supplementary
Table 1). We used principal component analysis to conﬁrm
ancestral comparability of cases and controls (Supplementary
Figure 1).
None of the six series showed a statistically signiﬁcant
difference in frequency of rs148744804 or rs76381440 genotype
between cases and controls (Table 1). In a meta-analysis of data
from all studies, we found no association between c.1451C or
c.2044T carrier status and CRC (OR¼ 1.14, 95% conﬁdence
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Table 1 | SEMA4A rs76381440 (p.Pro682Ser, c.2044C4T) and rs148744804 (p.Gly484Ala, c.1451G4C) genotype counts and
association statistics for the six colorectal cancer case–control studies.
Study Case Control OR (95% CI) P
AA AB BB Total MAF AA AB BB Total MAF
(A) rs76381440
England and Wales 0 152 3,514 3,666 0.021 2 259 5,879 6,140 0.021 0.97 (0.79–1.20) 0.80
Scotland 0 99 1,953 2,052 0.024 1 84 1,919 2,004 0.021 1.14 (0.85–1.54) 0.37
Holland 0 12 399 411 0.015 0 10 380 390 0.013 1.14 (0.49–2.68) 0.76
Spain 0 12 264 276 0.022 0 10 274 284 0.018 1.25 (0.53–2.93) 0.62
Portugal 0 1 198 199 0.003 0 7 179 186 0.019 0.13 (0.02–1.06) 0.06
Germany 0 9 243 252 0.018 0 27 1,060 1,087 0.012 1.44 (0.68–3.13) 0.34
Combined 0 285 6,571 6,856 0.021 3 397 9,691 10,091 0.020 1.04 (0.89–1.22) 0.63
(B) rs148744804
England/Wales 0 8 3,658 3,666 0.0011 0 13 6,127 6,140 0.0011 1.03 (0.43–2.49) 0.95
Scotland 0 6 2,046 2,052 0.0015 0 5 1,999 2,004 0.0012 1.17 (0.36–3.85) 0.79
Holland 0 0 411 411 0.0000 0 1 389 390 0.0013 NA NA
Spain 0 2 274 276 0.0036 0 1 283 284 0.0018 2.07 (0.19–22.9) 0.56
Portugal 0 1 198 199 0.0025 0 0 186 186 0.0000 NA NA
Germany 0 0 252 252 0.0000 0 0 1,087 1,087 0.0000 NA NA
Combined 0 17 6,839 6,856 0.0012 0 20 10,071 10,091 0.0010 1.14 (0.58–2.24) 0.71
NA¼ not applicable; MAF¼minor allele frequency; OR¼odds ratio; CI¼ conﬁdence interval. AA, AB and BB denote minor homozygote, heterozygote and major homozygote genotypes respectively.
Meta-analysis: Phet¼0.36, I2¼ 9.3%. Meta-analysis: Phet¼0.87, I2¼0%.
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Figure 1 | Forest plot of association between rs148744804 and rs76381440 SEMA4A genotypes and colorectal cancer risk. Studies were weighted
according to the inverse of the variance of the log of the OR calculated by unconditional logistic regression. Meta-analysis under a ﬁxed-effects model was
conducted using standard methods. Cochran’s Q statistic to test for heterogeneity and the I2 statistic to quantify the proportion of the total variation due to
heterogeneity were calculated. Horizontal lines indicate 95% conﬁdence intervals (CIs). Boxes indicate odds ratio (OR) point estimate; its area is
proportional to the weight of the study. Diamond (and broken line) indicates overall summary estimate, with CI given by its width. Unbroken vertical line
indicates null value (OR¼ 1.0).
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interval [CI]: 0.58–2.24, Pheterogenity¼ 0.87, I2¼ 0% and OR¼
1.04, 95% CI: 0.89–1.22, Pheterogenity¼ 0.36, I2¼ 9%, respectively;
Fig. 1). Principal component analysis adjustment had no impact
on ﬁndings.
Following on from these analyses we examined the mutational
spectra of SEMA4A in 1,006 familial early-onset CRC cases (Z1
ﬁrst-degree relative with CRC, o56yrs; 158 with FCCTX) from
the National Study of Colorectal Cancer Genetics (NSCCG)
and 1,609 1958 BC controls sequenced using Illumina Truseq
exome capture in conjunction with HiSeq2000 technology
(Supplementary Figure 2, Supplementary Table 2). Over 99% of
the SEMA4A transcript was covered at a depth greater than 10
reads (average coverage 38 , Supplementary Figure 2). We
identiﬁed 28 protein changing variants in 354 samples. Of these
variants, there were three unique frameshifts present in two
controls and one case. Overall, 13% of CRC cases (16% FCCTX)
had a protein changing variant in SEMA4A in comparison with
14% of controls.
There are a number of possible explanations for the disparity
between our ﬁndings and those reported by Sill and co-workers1.
Population stratiﬁcation can lead to spurious associations, and
this is especially important with rare variants. The study by Sill
and co-workers did not account for this and indeed in comparing
the frequency of rs14874408 included cases from both the US and
Germany, whereas we ensured ancestral comparability of case
patients and control subjects from single nucleotide poly-
morphism genotypes, thereby excluding this as a source of bias.
Generalisability is central to establishing a mutation–phenotype
relationship. The evidence for p.Val78Met being causative in
FCCTX is based on incomplete segregation in the family reported
by Schulz et al. Hence there is the issue of type 1 error.
Much of the missing heritability of CRC is likely to be a result
of high/moderate penetrance mutations and rare variants. As
illustrated by the recent identiﬁcation of POLE and POLD1 as a
cause of familial CRC4, this class of susceptibility is especially
important in understanding cancer biology and for clinical
practice. Hence there is a strong rationale for seeking to identify
additional such genes. Given the high frequency of deleterious
mutations carried by the healthy population, it is becoming
increasingly clear that robust and well-powered studies are
required to prevent erroneous ﬁndings from exome-sequencing
projects being asserted to be causal of disease.
In conclusion, in this well-powered study, we ﬁnd no evidence
to support variation in SEMA4A as a determinant of CRC risk.
Given that a priori SEMA4A is not a strong candidate CRC
predisposition gene, having previously been shown to cause eye
disease, we feel that caution should be exercised before SEMA4A
is considered as a cause of CRC.
References
1. Schulz, E. et al. Germline variants in the SEMA4A gene predispose to familial
colorectal cancer type X. Nat. Commun. 5, 5191 (2014).
2. Kinnersley, B. et al. Re: Role of the oxidative DNA damage repair gene OGG1
in colorectal tumorigenesis. J. Natl. Cancer Inst. 106, dju086 (2014).
3. Timofeeva, M. N. et al. Recurrent coding sequence variation explains only a small
fraction of the genetic architecture of colorectal cancer. Sci. Rep. 5, 16286 (2015).
4. Palles, C. et al. Germline mutations affecting the proofreading domains of
POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat.
Genet. 45, 136–144 (2013).
Acknowledgements
The Leeds collection was supported by Cancer Research UK programme award (C588/
A10589). MGD’s laboratory is supported by a Cancer Research UK programme grant
(C348/A12076). Funding for quality control of the 1958 Birth Cohort exome chip data
was through the Wellcome Trust Case Control Consortium. The Leiden study was
supported by the Dutch Cancer Society (UL2010-4656) and the Association for Inter-
national Cancer Research (10-0619). The Portuguese study was partly funded by the
Genetic study of Common Hereditary Bowel Cancers in Hispania and the Americas
(CHIBCHA) FP7 project and by Liga Portuguesa Contra o Cancro, Nu´cleo Regional do
Norte. Work in IT’s laboratory is supported by funding from the Oxford National
Institute for Health Research Biomedical Research Centre and core funding to the
Wellcome Trust Centre for Human Genetics from the Wellcome Trust (090532/Z/09/Z).
Work in the laboratory of RSH is supported by funding from Cancer Research UK
(C1298/A8362, supported by the Bobby Moore Fund). Additional funding is provided by
the National Health Service through the Biological Research Centre of the National
Institute for Health Research at the Royal Marsden Hospital National Health Service
Trust. BK is in receipt of a PhD Studentship from the Institute of Cancer Research and
received sponsorship from the Sir John Fisher Foundation. SCB is supported by a
contract from the Fondo de Investigacio´n Sanitaria (CP 03-0070). Centro de Investiga-
cio´n Biome´dica en Red en el A´rea tema´tica de Enfermedades Hepa´ticas y Digestivas
(CIBERehd) and Centro de Investigacio´n Biome´dica en Red de Enfermedades Raras
(CIBERER) are funded by the Instituto de Salud Carlos III. This work was supported by
grants from the Fondo de Investigacio´n Sanitaria/FEDER (PI14/00173, PI14/00230) and
Asociacio´n Espan˜ola contra el Ca´ncer (Fundacio´n Cientı´ﬁca GCB13131592CAST). We
are sincerely grateful to all patients participating in this study who were recruited in
25 (EPICOLON 1) and 14 (EPICOLON 2) Spanish hospitals as part of the EPICOLON
project. We are also indebted to the Spanish National Genotyping Center (Centro
Nacional de Genotipado, l Instituto de Salud de Salud Carlos III) and the Biobanks of
Hospital Clı´nic—IDIBAPS for technical help. The work was carried out (in part) at the
Esther Koplowitz Centre, Barcelona. This publication is supported by COST Action
BM1206. We acknowledge use of control genotypes from samples from the Lothian Birth
Cohort and Generation Scotland. The 1958 Birth Cohort exome chip data was QCd by
Kathy Stirrups. Data sharing was organized by the UK Exome-chip consortium. Exome-
chip design information: http://genome.sph.umich.edu/wiki/Exome_Chip_Design.
Exome variant server: http://evs.gs.washington.edu/EVS/. The 1958 Birth Cohort control
exomes include the ICR1000 dataset generated by Professor Nazneen Rahman’s Team in
the Division of Genetics & Epidemiology at The Institute of Cancer Research, London.
This control set is available to download from EGA: reference EGAD00001001021.
Author contributions
R.S.H. and B.K. designed the study. R.S.H., D.C. and B.K. drafted the manuscript, with
contributions from all authors. For the exome-chip project, B.K., S.B., M.N.T., S.C.-B.,
S.M.F., A.F., J.H., K.H., R.M.W.H., E.N., C.P., M.P., C.R.P., C.S., M.R.,T., H.W., T.W.,
D.T.B., I.T., M.G.D. and R.S.H. were involved in study design, sample collection and
assembly, data collection and quality control and/or data analysis for their respective
centres. For the exome-sequencing project B.K., D.C., S.E.D., M.F. and R.S.H. were
involved in study design and/or data analysis.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Kinnersley, B. et al. Correspondence: SEMA4A variation and
risk of colorectal cancer. Nat. Commun. 7:10611 doi: 10.1038/ncomms10611 (2016).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10611 CORRESPONDENCE
NATURE COMMUNICATIONS | 7:10611 | DOI: 10.1038/ncomms10611 | www.nature.com/naturecommunications 3
